

Vienna, Austria

Annual Congress of the
European Association of Nuclear Medicine

October 21 – 25, 2017
Vienna, Austria

Lunch Symposium – Blue Earth Diagnostics
Tuesday, October 24, 2017, 13:00 - 14:00, Hall K



Session Title

▼ Axumin™ (fluciclovine (18F)) - A Newly Approved Imaging Option for Recurrent Prostate Cancer A Scientific Update

Programme

- 13:00-13:05 **Welcome and introduction.**
Dr. Frode Willoch, MD, PhD, Faculty of Medicine, University of Oslo, Oslo, Norway
- 13:05-13.20 **Clinical Experience of fluciclovine (18F) PET/CT imaging in men with suspected recurrent prostate cancer and PSA values <1ng/mL.**
Dr. Frode Willoch, MD, PhD, Faculty of Medicine, University of Oslo, Oslo, Norway
- 13:20-13.35 **The FALCON Trial - A Phase 3 Study to assess the clinical utility of fluciclovine (18F) PET/CT imaging in patients with prostate cancer with biochemical recurrence.**
Dr. Eugene J. Teoh, MRCP, FRCR, Department of Oncology, University of Oxford, UK
- 13:35-13.50 **Practical experience of using fluciclovine (18F) in radiotherapy decision-making and field planning: preliminary results from a randomized controlled study.**
Prof. Ashesh B. Jani, MD, MSEE, Department of Radiation Oncology, Emory University School of Medicine, Atlanta, GA, US
- 13:50-14:00 **Summary and Closing remarks.**
Dr. Frode Willoch, MD, PhD, Faculty of Medicine, University of Oslo, Oslo, Norway